Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 13, 2008

BAC and Octapharma to Develop Custom Ligand for Recombinant Plasma Protein

  • BAC entered into a collaboration with Octapharma, a plasma protein company specializing in the development, production, and sale of plasma derivatives and recombinant plasma proteins. The objective of the collaboration is to discover and develop a custom CaptureSelect® ligand for the purification of a recombinant Factor IX product developed by Octapharma for the prophylaxis and treatment of bleeding in Haemophilia B.

    Octapharma will use the CaptureSelect ligand in the downstream processing of this protein from mammalian cell lines.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »